Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far

Therapeutics and Clinical Risk Management

关键词: afatinib;    squamous cell carcinoma;    epidermal growth factor receptor;    tyrosine kinase inhibitor;    non-small cell lung cancer;   

DOI  :  

来源: DOAJ

【 摘 要 】

Yijun Xu,1,2 Vivianne W Ding,1 Hong Zhang,2 Xun Zhang,2 David Jablons,1 Biao He11Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; 2Tianjin Chest Hospital, Tianjin, People’s Republic of ChinaAbstract: Compared to adenocarcinoma, fewer effective treatment options are available for advanced or metastatic squamous cell carcinoma (SCC) of the lung. Afatinib is an orally administered, irreversible EGFR antagonist. As a second-generation tyrosine kinase inhibitor, it has been applied in the treatment of patients with EGFR-mutant non-small-cell lung cancer. Recently, several clinical trials have shown that afatinib leads to a significant improvement in progression-free survival and overall survival of patients with SCC. Moving forward, afatinib should be one of the options among tyrosine kinase inhibitors, monoclonal antibodies, and cytotoxicity chemotherapy drugs for SCC.Keywords: afatinib, squamous cell carcinoma, EGFR, tyrosine kinase inhibitor, non-small-cell lung cancer, ErbB 

【 授权许可】

Unknown